CABA
Price
$2.54
Change
-$0.06 (-2.31%)
Updated
Jan 22 closing price
Capitalization
127.08M
49 days until earnings call
PRME
Price
$3.14
Change
-$0.04 (-1.26%)
Updated
Jan 23, 10:38 AM (EDT)
Capitalization
417.09M
42 days until earnings call
Ad is loading...

CABA vs PRME

Header iconCABA vs PRME Comparison
Open Charts CABA vs PRMEBanner chart's image
Cabaletta Bio
Price$2.54
Change-$0.06 (-2.31%)
Volume$954.43K
Capitalization127.08M
Prime Medicine
Price$3.14
Change-$0.04 (-1.26%)
Volume$503
Capitalization417.09M
CABA vs PRME Comparison Chart
Loading...
CABA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CABA vs. PRME commentary
Jan 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CABA is a StrongBuy and PRME is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 23, 2025
Stock price -- (CABA: $2.54 vs. PRME: $3.18)
Brand notoriety: CABA and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CABA: 30% vs. PRME: 145%
Market capitalization -- CABA: $127.08M vs. PRME: $417.09M
CABA [@Biotechnology] is valued at $127.08M. PRME’s [@Biotechnology] market capitalization is $417.09M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CABA’s FA Score shows that 1 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • CABA’s FA Score: 1 green, 4 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, CABA is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CABA’s TA Score shows that 2 TA indicator(s) are bullish while PRME’s TA Score has 3 bullish TA indicator(s).

  • CABA’s TA Score: 2 bullish, 4 bearish.
  • PRME’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, PRME is a better buy in the short-term than CABA.

Price Growth

CABA (@Biotechnology) experienced а +14.41% price change this week, while PRME (@Biotechnology) price change was +11.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.70%. For the same industry, the average monthly price growth was +2.32%, and the average quarterly price growth was -2.48%.

Reported Earning Dates

CABA is expected to report earnings on May 14, 2025.

PRME is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Biotechnology (+1.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($417M) has a higher market cap than CABA($127M). CABA YTD gains are higher at: 11.894 vs. PRME (8.904). CABA has higher annual earnings (EBITDA): -112.92M vs. PRME (-207.13M). CABA (183M) and PRME (176M) have equal amount of cash in the bank . CABA has less debt than PRME: CABA (15.2M) vs PRME (41.2M). PRME has higher revenues than CABA: PRME (800K) vs CABA (0).
CABAPRMECABA / PRME
Capitalization127M417M30%
EBITDA-112.92M-207.13M55%
Gain YTD11.8948.904134%
P/E RatioN/AN/A-
Revenue0800K-
Total Cash183M176M104%
Total Debt15.2M41.2M37%
FUNDAMENTALS RATINGS
PRME: Fundamental Ratings
PRME
OUTLOOK RATING
1..100
18
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
64

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CABAPRME
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 16 days ago
82%
Bearish Trend 16 days ago
86%
Momentum
ODDS (%)
Bearish Trend 16 days ago
86%
Bullish Trend 16 days ago
79%
MACD
ODDS (%)
Bullish Trend 16 days ago
84%
Bullish Trend 16 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 16 days ago
86%
Bullish Trend 16 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 16 days ago
88%
Bullish Trend 16 days ago
73%
Advances
ODDS (%)
Bullish Trend 17 days ago
87%
Bullish Trend 21 days ago
76%
Declines
ODDS (%)
Bearish Trend 25 days ago
87%
Bearish Trend 25 days ago
88%
BollingerBands
ODDS (%)
N/A
Bearish Trend 16 days ago
90%
Aroon
ODDS (%)
Bearish Trend 16 days ago
90%
Bearish Trend 16 days ago
84%
View a ticker or compare two or three
Ad is loading...
CABA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRGGX42.450.22
+0.52%
MFS Core Equity R1
JDSCX34.59-0.21
-0.60%
JPMorgan Small Cap Blend I
DHTYX24.89-0.16
-0.64%
Diamond Hill Select Y
IGNIX16.68-0.19
-1.13%
Macquarie Natural Resources I
RYUTX51.59-1.23
-2.33%
Rydex Utilities A

CABA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CABA has been loosely correlated with ARWR. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CABA
1D Price
Change %
CABA100%
-2.31%
ARWR - CABA
41%
Loosely correlated
-0.25%
ALLO - CABA
40%
Loosely correlated
+4.35%
IMNM - CABA
39%
Loosely correlated
+0.39%
PRME - CABA
39%
Loosely correlated
+9.28%
CRSP - CABA
39%
Loosely correlated
+6.48%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+9.28%
CRSP - PRME
63%
Loosely correlated
+6.48%
BEAM - PRME
61%
Loosely correlated
+7.58%
NTLA - PRME
59%
Loosely correlated
+10.76%
RXRX - PRME
55%
Loosely correlated
+8.87%
ABCL - PRME
54%
Loosely correlated
+15.36%
More